IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.
Aberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the development of diagnostic, prognostic and predictive biomarkers in human cancer, including colorectal cancer (CRC). The aim of this study was to perform a systematic and comprehensive analysis of a panel of...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4134211?pdf=render |
id |
doaj-05c8a15f9cbd4cf3913f1b00a5dd905d |
---|---|
record_format |
Article |
spelling |
doaj-05c8a15f9cbd4cf3913f1b00a5dd905d2020-11-25T02:32:23ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0198e10428510.1371/journal.pone.0104285IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer.Lucia Perez-CarbonellFrancesc BalaguerYuji ToiyamaCecilia EgoavilEstefania RojasCarla GuarinosMontserrat AndreuXavier LlorAntoni CastellsRodrigo JoverC Richard BolandAjay GoelAberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the development of diagnostic, prognostic and predictive biomarkers in human cancer, including colorectal cancer (CRC). The aim of this study was to perform a systematic and comprehensive analysis of a panel of CRC-specific genes as potential diagnostic, prognostic and predictive biomarkers in a large, population-based CRC cohort.Methylation status of the SEPT9, TWIST1, IGFBP3, GAS7, ALX4 and miR137 genes was studied by quantitative bisulfite pyrosequencing in a population-based cohort of 425 CRC patients.Methylation levels of all genes analyzed were significantly higher in tumor tissues compared to normal mucosa (p<0.0001); however, cancer-associated hypermethylation was most frequently observed for miR137 (86.7%) and IGFBP3 (83%) in CRC patients. Methylation analysis using the combination of these two genes demonstrated greatest accuracy for the identification of colonic tumors (sensitivity 95.5%; specificity 90.5%). Low levels of IGFBP3 promoter methylation emerged as an independent risk factor for predicting poor disease free survival in stage II and III CRC patients (HR = 0.49, 95% CI: 0.28-0.85, p = 0.01). Our results also suggest that stage II & III CRC patients with high levels of IGFBP3 methylation do not benefit from adjuvant 5FU-based chemotherapy.By analyzing a large, population-based CRC cohort, we demonstrate the potential clinical significance of miR137 and IGFBP3 hypermethylation as promising diagnostic biomarkers in CRC. Our data also revealed that IGFBP3 hypermethylation may serve as an independent prognostic and predictive biomarker in stage II and III CRC patients.http://europepmc.org/articles/PMC4134211?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lucia Perez-Carbonell Francesc Balaguer Yuji Toiyama Cecilia Egoavil Estefania Rojas Carla Guarinos Montserrat Andreu Xavier Llor Antoni Castells Rodrigo Jover C Richard Boland Ajay Goel |
spellingShingle |
Lucia Perez-Carbonell Francesc Balaguer Yuji Toiyama Cecilia Egoavil Estefania Rojas Carla Guarinos Montserrat Andreu Xavier Llor Antoni Castells Rodrigo Jover C Richard Boland Ajay Goel IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. PLoS ONE |
author_facet |
Lucia Perez-Carbonell Francesc Balaguer Yuji Toiyama Cecilia Egoavil Estefania Rojas Carla Guarinos Montserrat Andreu Xavier Llor Antoni Castells Rodrigo Jover C Richard Boland Ajay Goel |
author_sort |
Lucia Perez-Carbonell |
title |
IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. |
title_short |
IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. |
title_full |
IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. |
title_fullStr |
IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. |
title_full_unstemmed |
IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. |
title_sort |
igfbp3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Aberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the development of diagnostic, prognostic and predictive biomarkers in human cancer, including colorectal cancer (CRC). The aim of this study was to perform a systematic and comprehensive analysis of a panel of CRC-specific genes as potential diagnostic, prognostic and predictive biomarkers in a large, population-based CRC cohort.Methylation status of the SEPT9, TWIST1, IGFBP3, GAS7, ALX4 and miR137 genes was studied by quantitative bisulfite pyrosequencing in a population-based cohort of 425 CRC patients.Methylation levels of all genes analyzed were significantly higher in tumor tissues compared to normal mucosa (p<0.0001); however, cancer-associated hypermethylation was most frequently observed for miR137 (86.7%) and IGFBP3 (83%) in CRC patients. Methylation analysis using the combination of these two genes demonstrated greatest accuracy for the identification of colonic tumors (sensitivity 95.5%; specificity 90.5%). Low levels of IGFBP3 promoter methylation emerged as an independent risk factor for predicting poor disease free survival in stage II and III CRC patients (HR = 0.49, 95% CI: 0.28-0.85, p = 0.01). Our results also suggest that stage II & III CRC patients with high levels of IGFBP3 methylation do not benefit from adjuvant 5FU-based chemotherapy.By analyzing a large, population-based CRC cohort, we demonstrate the potential clinical significance of miR137 and IGFBP3 hypermethylation as promising diagnostic biomarkers in CRC. Our data also revealed that IGFBP3 hypermethylation may serve as an independent prognostic and predictive biomarker in stage II and III CRC patients. |
url |
http://europepmc.org/articles/PMC4134211?pdf=render |
work_keys_str_mv |
AT luciaperezcarbonell igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT francescbalaguer igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT yujitoiyama igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT ceciliaegoavil igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT estefaniarojas igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT carlaguarinos igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT montserratandreu igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT xavierllor igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT antonicastells igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT rodrigojover igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT crichardboland igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer AT ajaygoel igfbp3methylationisanoveldiagnosticandpredictivebiomarkerincolorectalcancer |
_version_ |
1724819567904030720 |